Orgenesis Inc Share Price Today: Live Updates & Key Insights

Orgenesis Inc share price today is $2.25, up -34.84%. The stock opened at $1.95 against the previous close of $3.238, with an intraday high of $2.37 and low of $1.9283.

Orgenesis Inc Share Price Chart

Orgenesis Inc

us-stock
To Invest in {{usstockname}}
us-stock

Orgenesis Inc Share Price Performance

$2.25 -0.3484(-34.84%) ORGS at 23 Mar 2026 02:37 PM Biotechnology
Lowest Today 1.9283
Highest Today 2.37
Today’s Open 1.95
Prev. Close 3.238
52 Week High 10.80
52 Week Low 1.93
Day’s Range: Low 1.9283 High 2.37
52-Week Range: Low 1.93 High 10.80
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

Orgenesis Inc Institutional Holdings

Vanguard Group Inc 1.91

Vanguard Total Stock Mkt Idx Inv 1.19

Vanguard Institutional Extnd Mkt Idx Tr 0.63

Geode Capital Management, LLC 0.59

Fidelity Extended Market Index 0.37

BlackRock Inc 0.17

State Street Corp 0.17

BlackRock Extended Equity Market K 0.11

Fidelity Total Market Index 0.09

Northern Trust Corp 0.08

Vanguard Balanced Index Inv 0.07

Bank Hapoalim BM 0.07

Renaissance Technologies Corp 0.06

Fidelity Series Total Market Index 0.06

SSgA U.S. Extended Market Index Class I 0.04

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - L 0.04

CAMBRIDGE Invest RESEARCH ADVISORS, INC. 0.04

NT Ext Equity Mkt Idx Fd - NL 0.04

XTX Topco Ltd 0.03

Spartan Total Market Index Pool E 0.03

Fidelity Nasdaq Composite Index 0.03

Vanguard Instl Ttl Stck Mkt Idx Tr 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Spartan Extended Market Index Pool E 0.03

Virtu Financial LLC 0.03

Vanguard U.S. Eq Idx £ Acc 0.02

Extended Equity Market Fund M 0.01

UBS Group AG 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

Northern Trust Wilshire 5000 0.00

Tower Research Capital LLC 0.00

Bank of America Corp 0.00

Royal Bank of Canada 0.00

JPMorgan Chase & Co 0.00

BNP Paribas Arbitrage, SA 0.00

Jane Street Group LLC 0.00

Prudential Financial Inc 0.00

Qube Research & Technologies 0.00

Wells Fargo & Co 0.00

Orgenesis Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Orgenesis Inc Fundamentals

Market Cap 15.45 M

PB Ratio 1.2558

PE Ratio 0.0

Enterprise Value 29.12 M

Total Assets 14.55 M

Volume 486287

Orgenesis Inc Company Financials

Annual Revenue FY23:530000 0.5M, FY23:27753000 27.8M, FY22:36025000 36.0M, FY21:35502000 35.5M, FY20:7652000 7.7M

Annual Profit FY23:-5725000 -5.7M, FY23:3364000 3.4M, FY22:15585000 15.6M, FY21:7342000 7.3M, FY20:-22966000 -23.0M

Annual Net worth FY23:-55361000 -55.4M, FY23:-25066000 -25.1M, FY22:-12169000 -12.2M, FY21:-18059000 -18.1M, FY20:-95127000 -95.1M

Quarterly Revenue Q2/2024:246000 0.2M, Q1/2024:141000 0.1M, Q4/2023:-13599000 -13.6M, Q3/2023:110000 0.1M, Q3/2023:110000 0.1M

Quarterly Profit Q2/2024:-749000 -0.7M, Q1/2024:-617000 -0.6M, Q4/2023:-13761000 -13.8M, Q3/2023:-29000 -0.0M, Q3/2023:-29000 -0.0M

Quarterly Net worth Q2/2024:-8904000 -8.9M, Q1/2024:-9765000 -9.8M, Q4/2023:-34392000 -34.4M, Q3/2023:12653000 12.7M, Q3/2023:12653000 12.7M

About Orgenesis Inc & investment objective

Company Information Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Organisation Biotechnology

Employees 146

Industry Biotechnology

CEO Ms. Vered Caplan M.Sc.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Orgenesis Inc FAQs

What is the share price of Orgenesis Inc today?

The current share price of Orgenesis Inc is $2.25.

Can I buy Orgenesis Inc shares in India?

Yes, Indian investors can buy Orgenesis Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Orgenesis Inc shares in India?

You can easily invest in Orgenesis Inc shares from India by:

Can I buy fractional shares of Orgenesis Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Orgenesis Inc?

Orgenesis Inc has a market cap of $15.45 M.

In which sector does Orgenesis Inc belong?

Orgenesis Inc operates in the Biotechnology sector.

What documents are required to invest in Orgenesis Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Orgenesis Inc?

The PE ratio of Orgenesis Inc is N/A and the PB ratio is 1.26.